AstraZeneca and Mitsubishi Tanabe are advancing AZD4144, a novel NLRP3 inhibitor, through Phase I trials in healthy volunteers, exploring new chemotypes.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.